Ziritaxestat

Ziritaxestat (GLPG1690) is a first-in-class autotaxin (ATX) inhibitor, with an IC50 of 131 nM and a Ki of 15 nM[1].

Product Specifications

CAS Number

[1628260-79-6]

Product Name Alternative

GLPG1690

UNSPSC

12352005

Hazard Statement

H315, H317, H318, H334, H335, H341, H361, H370, H413

Target

Phosphodiesterase (PDE)

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/GLPG1690.html

Concentration

10mM

Purity

99.93

Solubility

DMSO : 41.67 mg/mL (ultrasonic)

Smiles

N#CC1=C(C2=CC=C(F)C=C2)N=C(N(C3=C(CC)N=C4C(C)=CC(N5CCN(CC(N6CC(O)C6)=O)CC5)=CN43)C)S1

Molecular Formula

C30H33FN8O2S

Molecular Weight

588.70

Precautions

H315, H317, H318, H334, H335, H341, H361, H370, H413

References & Citations

[1]Desroy N, et al. Discovery of 2-[[2-Ethyl-6-[4-[2- (3-hydroxyazetidin-1-yl) -2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4- (4-fluorophenyl) thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis. J Med Chem. 2017 May 11;60 (9) :3580-3590.